Arbutus Biopharma Corporation ABUS Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Collaborations and licenses | $11.49M+167% | $12.6M+222% | $12.87M+238% | $13.35M+91.5% | $4.3M-55.7% | |
| Non-cash royalty revenue | $1.22M-42.3% | $1.48M-34.2% | $1.74M-40.8% | $2.06M-33.2% | $2.11M-35.8% | |
| Revenue from collaborations and licenses | $188.64M+6,942% | $10.71M+318% | $11.3M+384% | $11.66M+138% | $2.68M-63.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Arbutus Biopharma Corporation break its business down?
- Arbutus Biopharma Corporation (ABUS) reports revenue by product across 3 parts — Collaborations and licenses, Non-cash royalty revenue and Revenue from collaborations and licenses. Each is extracted from the segment footnotes and tracked over time.
- Where does Arbutus Biopharma Corporation's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Arbutus Biopharma Corporation's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
